Drug for sepsis to be tested for COVID-19-THE HINDU-22-04-2020
Sepsivac, a drug jointly developed by the Ahmedabad-based Cadilla Pharmaceuticals and the Council for Scientific and Industrial Research , will be tested in 50 COVID-19 patients at the All-India Institute of Medical Sciences in Delhi and Bhopal, and Post Graduate Institute of Medical Education and Research, Chandigarh. Results from a human trial are expected in the next two months, Ram Vishwakarma, Director, Indian Institute of Integrative Medicine, Jammu, told The Hindu.
Sepsivac reduces the days on ventilator, in ICU and hospital and incidence of secondary infection, Cadilla Pharmaceuticals have claimed on their website. The United States and Australia are also going to start testing the efficacy of the BCG, or tuberculosis vaccine, that also employs a different strain of mycobacterium, in health care workers at the frontline of treating COVID-19 patients.